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ABSTRACT
Introduction. Hypoglycemia is one of the side effects of 
glibenclamide, which is administered orally in people 
with diabetes. Hypoglycemia may occur easily due to 
the reduced metabolism of this drug in patients with 
chronic kidney disease. The aim of this study was to 
compare the incidence of hypoglycemia in patients 
with chronic kidney disease who were treated with 
glibenclamide or insulin.
Material and methods. In this study, 87 patients with 
type 2 diabetes and in stage 3–4 of chronic kidney dis-
ease (CKD) were examined. The patients were divided 
into two groups of glibenclamide (N = 44) and insulin 
(N = 43) based on the type of blood glucose-lowering 
therapy. Next, demographic data, serum creatinine 
level, number of hypoglycemic episodes over the last 
year and the amount of consumed drugs were re-
corded in the checklist. Finally, the data analysis was 
performed using the SPSS Software.
Results. There was no significant difference between 
the two groups in terms of age, estimated glomerular 
filtration rate (eGFR), weight, duration of diabetes 
and blood glucose control. In addition, it was in-
dicated that 38% of patients in the glibenclamide 
group and 32% of patients in the insulin group had 
at least one hypoglycemic episode. Also, in those two 
groups, there was no significant correlation between 
doses of the drug and the number of hypoglycemic 
episodes.
Conclusions. This study showed that there was no sig-
nificant difference between the patients with chronic 
kidney disease who were treated with insulin and those 
patients who were treated with glibenclamide in terms 
of number of symptomatic hypoglycemic episodes. 
(Clin Diabetol 2018; 7, 3: 159–163)
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Introduction
Diabetes is the most common endocrine disorders 
in the world and its prevalence is rising (in 1980, 4.7% 
of individuals over the age of 18 were afflicted with dia-
betes but the latter percentage increased up to 8.5% in 
2014). In 2015, it was estimated that 1.5 million deaths 
were directly caused by diabetes. In 2012, 2.2 million 
deaths were associated with high blood glucose [1].
The renal failure is one of the complications of 
diabetes and several studies indicate that the primary 
cause of renal failure is diabetes among 25% of patients 
with renal failure and 50% of patients with end stage 
renal disease (ESRD) [2, 3]. It is impossible to prevent 
the progression of renal failure and other complications 
of diabetes, except by controlling the blood glucose in 
these patients. Many patients tend to get oral glucose-
lowering drugs. According to the National Health and 
Nutrition Examination Survey, 62.9% of patients with 
CKD stages 4–5 receive at least one oral glucose-low-
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ering drug [4]. The metabolism of many drugs widely 
used in the treatment of diabetes is dependent on the 
kidney. As a result, these drugs are contraindicated 
or they require dose adjustments to prevent hypo-
glycemic episodes, lactic acidosis and other possible 
complications. Besides, review studies and guidelines 
do not adopt any definite approach towards using 
these drugs [5]. As such, the clinical opinions of physi-
cians are different in the use of these drugs. A study 
was conducted on 301 patients in stage 3 to stage 
5 of CKD and the results indicated that, based on the 
guideline on chronic kidney disease patients [6], 53% 
of them took drug or doses outside of the proposed 
recommendation, of which 24.4% were treated with 
the glibenclamide [7]. Another study was conducted in 
France and it was found that the general practitioners 
and diabetes specialists did not take into account the 
proposed recommendations and, thus, they prescribed 
metformin for 63% of patients with stage 3 of CKD 
and 33% of patients with stage 4 of CKD. Also, they 
prescribed sulfonylureas for 51% and 61% of patients 
with stage 3 and stage 4 of CKD, respectively [8]. 
As noted, sulfonylureas are among the drugs that 
are used regardless of proposed recommendations. 
Although these drugs are involved in controlling blood 
glucose by stimulating the secretion of insulin, the same 
mechanism can put patients at increased risk for hypo-
glycemia. Actually, the risk of hypoglycemia increases 
in patients who have decreased level of GFR. The cause 
of this increased risk in patients with renal failure can 
be summarized as follows: 1) decreased level of insulin 
clearance and the oral drug itself [5] and 2) decreased 
level of gluconeogenesis due to loss of kidney mass [9]. 
For this reason, many researchers have forbidden the 
use of glibenclamide in patients with chronic kidney 
disease stages 3–5 [10].
Considering the refusal of many patients to ac-
cept insulin therapy and the costly use of existing oral 
drugs in the treatment of renal failure, many patients 
still tend to use these drugs, despite being aware of 
the side effects of oral drugs such as glibenclamide. 
Accordingly, the aim of this study was to compare the 
prevalence of hypoglycemia in patients with renal fail-
ure who were treated with glibenclamide and patients 
who received insulin.
Materials and methods
The study was conducted in a historical cohort 
design. As such, the medical records of all diabetic 
patients in stage 3 and stage 4 of CKD, who were 
referred to nephrology clinics from March 21, 2011 to 
September 21, 2015 in Qom province, were reviewed. 
In total, the medical records of 107 patients treated 
with glibenclamide or insulin were extracted. Next, 
the medical records of patients that were followed for 
at least 1 year to control the blood glucose and were 
checked up at least for 10 sessions during this period 
were selected. As such, other medical records were 
excluded from the study. Finally, 87 medical records 
were included in the study based on the entry criteria 
for the study. The medical records of 20 other patients 
were also examined. According to available data and 
after contacting the patients, it was found that there 
was no significant difference between these 20 medical 
records and the 87 medical records in terms of hypo-
glycemia occurrence.
Those patients who presented with renal failure 
for at least 3 months or more were diagnosed as CKD 
patients. Accordingly, all patients who were at stage 3 
of CKD or higher were included in the study. Besides, 
the patients’ GFR was calculated using the Cockcroft-
-Gault formula based on gender, weight, age and serum 
creatinine (GFR={((140–age) × weight)/(72 × SCr)} × 
0.85 (if female)).
Furthermore, the patients’ medical records were 
investigated in terms of demographic variables, type 
of diabetes treatment and incidence of hypoglycemia. 
Given the one-year follow up, it was attempted to make 
use of neurological and neuroglycopenic symptoms 
as well as patients’ remarks in order to determine the 
incidence of hypoglycemia. Hypoglycemia episode is 
defined as an event with symptoms of hypoglycemia 
which was associated with a blood glucose level below 
50 mg/dL or prompt recovery after oral carbohydrate 
ingestion or intravenous glucose administration.
All patients were informed about the side effects of 
medications and hypoglycemia symptoms at the onset 
of their treatment, and in each visit they were asked 
about hypoglycemia symptoms and episodes.
Having collected the required information, all the 
data was analyzed using the SPSS Statistical Software 
(Version 22). Regarding the quantitative variables, it 
was decided to calculate the mean and standard devia-
tion. Given the qualitative variables, it was endeavored 
to calculate the absolute and relative frequency. In this 
analysis, frequency distribution and prevalence indices 
as well as statistical T-test and Chi-Square Test with a 
significant level of less than 0.05 were used. In addi-
tion, the logistic regression was implemented to inves-
tigate the impact of forenamed factors, such as type 
of treatment, on hypoglycemia. Finally, the Spearman 
correlation coefficient was used to check the correla-
tion between the drug dose and number of episodes.
The information was extracted confidentially and 
the results were announced in a group-based format. 
Patients were fully aware of complications of gliben-
Mohammad Aghaali, Hossein Saghafi, Incidence of hypoglycemia episodes in diabetic patients
161
clamide, but their unwillingness to use insulin led the 
researchers to treat them with glibenclamide.
Results
In this study, 87 diabetic patients in stage 3 and 4 
of CKD were studied. In fact, 43 patients were treated 
with insulin and 44 patients received glibenclamide. 
Table 1 shows the distribution of patients according to 
the type and the dose of treatment. The patients were 
divided into two groups of glibenclamide (N = 44) 
and insulin (N = 43) based on the type of blood 
glucose-lowering therapy.
It was found that, except for the gender based dis-
tribution, there was no significant difference between 
the two groups regarding the study variables (age, GFR, 
weight and duration of diabetes). Besides, it was found 
that there was no significant difference in blood glu-
cose control between two groups of patients (Tab. 2).
It was indicated that 17 patients (38.6%) in the 
glibenclamide treated group and 14 patients (32.6%) 
in the insulin treated group experienced symptomatic 
hypoglycemia within a one-year of follow up. However, 
the findings indicated that the difference was not sta-
tistically significant (p = 0.557). This study showed that 
there was no significant difference between the two 
groups in terms of number of hypoglycemic episodes. 
The mean number of hypoglycemic episodes in the 
glibenclamide-treated and insulin-treated groups were 
1.89 ± 1.33 and 1.98 ± 1.61 (p = 0.776) respectively.
No correlation was found between glibenclamide 
dose (r = 0.103, p = 0.504) or insulin dose (r = 0.124, 
p = 0.253) and the number of hypoglycemic episodes 
based on the result of the Spearman correlation coef-
ficient.
The logistic regression showed that, among the 
variables studied in this study, there was only a signifi-
cant relationship between patients’ age and incidence 
of hypoglycemia (Tab. 3).
Discussion
This study was conducted due to observation 
thaat patients with renal failure are willing to use 
glibenclamide in spite of its most important complica-
tion, hypoglycemia. Despite the contraindication to use 
Table 1. Distribution of patients according to the type and 
dose of treatment
Treatment Frequency Percent Cumulative 
percent
Glibenclamide (5 mg) 13 14.9 14.9
Glibenclamide (7.5 mg) 5 5.7 20.6
Glibenclamide (10 mg) 8 9.2 29.8
Glibenclamide (12.5 mg) 1 0.1 29.9
Glibenclamide (15 mg) 6 6.9 36.8
Glibenclamide (20 mg) 11 12.6 49.4
Insulin 43 50.6 100
Table 2. Comparison between the two groups regarding the under study variables
Variable Glibenclamide group Insulin group p-value*
Male to female ratio 2.76 1.05 0.038
Age (year), mean ± SD 69.02 ± 9.77 64.58 ± 17.48 0.146
Weight [kilogram], mean ± SD 75.73 ± 12.16 75.37 ± 14.6 0.902
Diabetes duration (year), mean ± SD 13.43 ± 8.33 15.1 ± 10.52 0.360
GFR [mL/min/1.73 m2], mean ± SD 35.57 ± 16.37 31.82 ± 15.95 0.282
FBG [mg/dL], mean ± SD 110.02 ± 61.4 120.07 ± 77.4 0.547
HbA1c (percent), mean ± SD 5.54 ± 3.66 5.32 ± 3.67 0.774
*P-value with 2-tailed, unpaired t-test. FBG — fasting blood glucose
Table 3. Effects of study variables on hypoglycemic episode by logistic regression
B S.E. Wald df Sig. Exp(B) 95% C.I. for EXP(B)
Lower Upper
Treatment type (glibenclamide) 0.039 0.478 0.007 1 0.936 1.039 0.408 2.651
Gender (male) 0.457 0.502 0.831 1 0.362 1.580 0.591 4.224
Age (year) 0.046 0.024 3.857 1 0.050 1.048 1.000 1.097
GFR [mL/min] 0.005 0.015 0.095 1 0.757 1.005 0.976 1.034
Constant –4.229 1.815 5.429 1 0.020 0.015
S.E. — standard error; df — degrees of freedom; Sig. — significance
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gli benclamide in patients with CKD (Stage 3 onwards), 
many patients do not accept insulin therapy due to 
problems they face in using such a drug. On the other 
hand, oral antidiabetic drugs used in renal failure are 
either not available or at a higher cost. The results of 
this study indicated that many patients still tended to 
use these drugs, despite being aware of the side effects 
of oral drugs such as glibenclamide. Similarly, previous 
studies have shown that 18% to 61% of patients in stage 
3 and higher stages of CKD have been treated with sulfo-
nylureas, which has been a forbidden practice [7, 8, 11].
This non-compliance with the guidelines can be 
attributed to different reasons. In some studies, part 
of this lack of compliance was attributed to physicians’ 
lack of knowledge and information. However, in the 
present study, the physicians and patients were aware 
of the contraindications to the drug use. Other causes 
have also been mentioned in studies; for example, pa-
tients argue that oral drugs are effective and easier to 
use and, unlike insulin, the oral drugs do not require 
daily doses adjustment. Insulin administration is asso-
ciated with high risk of hypoglycemia in patients with 
renal failure [9, 12, 13].
The results of this study did not show a significant 
difference between insulin treated and glibenclamide 
treated groups in terms of incidence of symptomatic 
hypoglycemia. However, previous studies have shown 
different results in this regard. Studies conducted on 
diabetic patients with normal kidney function have 
reported hypoglycemia rates between 0.2 and 1.8 in 
return for 100 person-years among users of sulfony-
lurea [14–16]. Regarding the other five studies that 
examined hypoglycemia caused by sulfonylureas in 
patients with renal failure, it was indicated that one 
study, similar to the present one, did not show any 
association between glibenclamide consumption and 
hypoglycemia [17]. However, the other four studies 
showed that the risk of hypoglycemia was higher in 
patients who used sulfonylureas than those patients 
who used other drugs [18–20].
Van Dalem et al. showed that there was an as-
sociation between using sulfonylureas and the risk 
of hypoglycemia. Actually, the incidence rates of hy-
poglycemia in patients who have just started taking 
drug and those who have recently started taking the 
drug were 13.5 in 1000 person-years and 4.6 in 1000 
person-years, respectively. Besides, they found that the 
incidence rate of hypoglycemia in patients who already 
took drug was 0.6 in 1000 person-years [21]. Given the 
present study, it was indicated that since all patients 
were already treated with these drugs, the difference 
between the present study and the rest of the studies 
could be attributed to the former reason. 
There are some evidences that argue that sulfonylu-
reas should not be used in patients with chronic kidney 
disease stage 3–5. For example, researchers believe that 
the risk for hypoglycemia is high in patients with renal 
failure because these patients are characterized with 
reduced clearance of sulfonylureas and insulin. On the 
other hand, due to decreased level of renal gluconeo-
genesis, these patients can deal with hypoglycemia to 
a lesser extent and power. Also, reduced level of ap-
petite caused by uremia can also increase the risk of 
hypoglycemia in these patients [17, 22–24]. Further-
more, studies have shown that severe hypoglycemia 
can debilitate the prognosis of these patients in that the 
mortality rate of patients who once experienced severe 
hypoglycemia is 1.4 times more than that of the rest 
of the patients [25]. Also, the risk of death is very high 
over 90 days after a severe hypoglycemic attack [26]. 
Conversely, there are some evidences (e.g. the 
results of the present study) that undermine the ab-
solute ban on using sulfonylureas (e.g. glibenclamide) 
in patients in stage 3 of CKD and higher. Weir et al. 
undertook a nested case-control study and found that 
there was no relationship between renal failure and 
the risk of hypoglycemia caused by glibenclamide [17]. 
Interestingly, the studies that showed that there was 
a relationship between death and hypoglycemia could 
not prove that the latter relationship was a causal one 
[27]. Besides, the pharmacokinetic studies conducted 
on glibenclamide showed that there was no correlation 
between creatinine clearance (29–131 ml/min/1.73 m2) 
and glibenclamide clearance [28].
Conclusions
Regarding the findings of this study and the results of 
similar recent studies on such oral glucose-lowering drugs 
as glibenclamide, it can be argued that the ban on using 
sulfonylureas in CKD of stage 3 onwards can be revised.
It seems that failure to compare the severity of 
hypoglycemia in the two groups and the lack of inves-
tigation of patients’ survival can be considered among 
the limitations of this study. Thus, it is suggested that 
further studies can be conducted on this subject. If 
this misleading belief is rejected, the physicians can 
prescribe glibenclamide as a cheap and less side effect 
drug in many diabetic patients who are diagnosed with 
chronic kidney disease caused by diabetic nephropathy.
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